Medivive is a prescriber-only platform for licensed medical professionals (MD, DO, NP, PA). The NAD+ pen is available exclusively through physician prescription and is not sold directly to patients or consumers.
The Medivive NAD+ pen is the only product on the US market that originates from a full drug development program. SpectrumX, our UK development partner, holds a Medical Specials license. The formulation was transferred via formal tech transfer to VeV Scientific, an FDA-registered cGMP 503B outsourcing facility in San Diego.
This is not a bulk-compounded product. It is a drug-developed formulation manufactured in an ISO-class cleanroom with sterility and endotoxin testing on every batch and Certificate of Analysis availability.
The Medivive NAD+ pen is designed to create meaningful recurring revenue with minimal operational overhead.
You do not stock or store product. The pharmacy ships directly to patients.
Patients self-administer at home. No IV setup and no long in-office infusion visits.
Auto-refill availability supports predictable monthly continuity for your practice.
Pricing and margin details are available to verified physicians after account creation or by contacting our team directly.
Complete onboarding with practice details, NPI, state licenses, and photo ID. Approval is typically within one business day.
Set your practice payment method. Charges occur when prescriptions are submitted.
Enter patient demographics, relevant history, and shipping details.
Select dosing, confirm details, and submit. Chemistry Rx is assigned automatically.
Each prescription supports up to 11 refills. Auto-refill can notify your practice 3 days in advance.
You bill your patient separately. The Medivive platform does not collect patient payments.
| Product | Prefilled NAD+ subcutaneous injector pen |
|---|---|
| Origin | Developed by SpectrumX (UK) through a full drug development program |
| Contents | 1,000 mg NAD+ per pen (30-day supply) |
| Dose Selector | 1 unit = 3.33 mg NAD+ |
| Standard Dosing | 100 mg (30 units) every 3 days, or 10 units daily with physician titration |
| Route | Subcutaneous (abdomen or thigh) |
| Manufacturer | VeV Scientific, FDA-registered cGMP 503B outsourcing facility, San Diego, CA |
| Dispensing Pharmacy | Chemistry Rx, PCAB-accredited and LegitScript-certified 503A pharmacy |
| Shipping | Cold-chain, 2-day FedEx direct to patient |
| Storage | Refrigerate 2-8C (36-46F). Do not freeze. Protect from light. |
| Refills | Up to 11 refills per prescription with optional auto-refill |
| Availability | 41 states (not available in AL, AZ, AR, CA, ID, IA, MS, NJ, OR) |
Potential side effects: Injection site reactions, flushing, nausea, and headache have been reported with parenteral NAD+ administration. Peer-reviewed subcutaneous outcome literature remains limited.
Precautions: Not recommended during pregnancy or lactation due to limited safety data. Use clinician judgment for patients with cardiovascular risk factors.
Storage: Refrigerate at 2-8C, do not freeze, and protect from light.
Create your provider account, request a complimentary sample, or schedule a call with our team.